Abzena, an integrated CDMO and CRO specializing in complex biologics and bioconjugates, has launched a new Scientific Advisory Board (SAB) to support its innovation and growth strategy.

The board brings together industry veterans with extensive expertise in drug development, CMC, and regulatory strategy across the biopharmaceutical value chain.

The move comes as the company continues to expand its capabilities in advanced modalities, including antibody-drug conjugates (ADCs), antibody-oligonucleotide conjugates (AOCs), and bispecifics.

According to the company, the SAB will provide strategic oversight and expert evaluation of current and future technologies to enhance client programs and accelerate the path from research to patients.

A strategic move to strengthen scientific direction

Abzena’s CEO, Matt Stober, said the board was formed to help shape the company’s future direction and ensure it remains at the forefront of innovation in biologics. “These experts will help evaluate our strategies and recommend improvements to better support complex programs and deliver medicines to patients faster,” he said.

Chief Commercial Officer Joe Principe added that the advisory board members bring deep knowledge from both industry and regulatory landscapes. “Their collective experience will be vital as we continue through a significant phase of growth,” he said.

Board member expertise spans R&D, CMC, and commercialization

The inaugural board includes a broad mix of leaders from across the drug development spectrum:

• John Knight, PhD – Founder of JKONSULT, with 38 years in process chemistry and early clinical trial material supply, including past roles at GSK, Vernalis, and Evotec.
• Kamal Egodage, PhD, MBA – Former executive at Eli Lilly, Novartis, and Monsanto, now advising on end-to-end biologics development and regulatory strategy.
• Morris Rosenberg, DSc – Consultant with a track record in ADC and biosimilar development at Seattle Genetics, Immunomedics, and Biogen, involved in the launch of multiple therapies.
• Scott Rudge, PhD – SVP at Margaux Biologics and board member at Syner-G BioPharma Group, with more than three decades of experience in process development and manufacturing.
• Steven Sandoval – Founder of PTSI, supporting technical operations across gene therapy, vaccines, mRNA, and cell therapy, with prior leadership at Amgen and Pfenex.
• Tatyana Touzova – Chief pharmaceutical development officer at SERA Medicines, with 35+ years in CMC strategy, global regulatory submissions, and clinical-stage operations for biologics.

Abzena said the board will meet regularly to evaluate scientific priorities and technology roadmaps, supporting both internal innovation and external collaboration with biopharma partners.